Ventana benchmark xt

Manufactured by Leica Microsystems

Sourced in Germany

The Ventana BenchMark XT is an automated slide staining system for immunohistochemistry (IHC) and in situ hybridization (ISH) applications. The system is designed to provide consistent and reliable results by automating the slide staining process, reducing manual handling, and improving workflow efficiency.

Automatically generated - may contain errors

Lab products found in correlation

Bond max, by Leica Microsystems (1 mentions) Ab26056, by Abcam (1 mentions) Ab53281, by Abcam (1 mentions) Ab236465, by Abcam (1 mentions) Ab53715, by Abcam (1 mentions) Anti ephb2, by R&D Systems (1 mentions) Anti cd44, by Leica Biosystems (1 mentions) Anti β catenin, by Leica Biosystems (1 mentions) Anti smoc2, by OriGene (1 mentions)

4 protocols using ventana benchmark xt

Immunohistochemical Profiling of ccRCC Biomarkers

Check if the same lab product or an alternative is used in the 5 most similar protocols

A total of 25 antibodies were selected as (i) they are involved in the
VHL signaling pathway, (ii) they are known to be prognostic
biomarkers of ccRCC and (iii) they have been reported as markers of ccpRCCs and
RATs in a small group of ccpRCCs described in recent USCAP meetings
(2011–2014). TMA sections (2.5 μm) were transferred to glass
slides and treated using Ventana Benchmark XT, Bond-max (Leica Microsystems)
automated systems, as well as manual protocols. TMA construction was not
possible in five of the ccpRCC cases due to absence of tissue. The
immunohistochemical staining product was described as nuclear, membranous or
cytoplasmic (Table 2). The
immunohistochemistry results were interpreted as 0 (negative), 1+ (weak
staining), 2+ (moderate staining) and 3+ (strong staining). For
statistical analysis all 2+ and 3+ stainings were defined as
positive, 0 and 1+ as negative. Antibodies and protocols are listed in
Table 2.

Deml K.F., Schildhaus H.U., Compérat E., von Teichman A., Storz M., Schraml P., Bonventre J.V., Fend F., Fleige B., Nerlich A., Gabbert H.E., Gaβler N., Grobholz R., Hailemariam S., Hinze R., Knüchel R., Lhermitte B., Nesi G., Rüdiger T., Sauter G, & Moch H. (2015). Clear Cell Papillary Renal Cell Carcinoma and Renal Angiomyoadenomatous Tumor – Two Variants of a Morphologic, Immunohistochemical and Genetic Distinct Entity of Renal Cell Carcinoma. The American journal of surgical pathology, 39(7), 889-901.

+ Open protocol

+ Expand

Immunohistochemical Analysis of Hedgehog Pathway

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunohistochemistry (IHC) was performed on 4-μm TMA sections using a Ventana BenchMark XT Staining systems (Leica Microsystems, Wetzlar, Germany) according to the manufacturer’s instructions. The primary antibodies used are as follows: anti-GLI1 (Cell signaling, #3538), anti-GLI2 (Abcam, ab26056), anti-PTCH1 (Abcam, ab53715), anti-PTCH2 (Abcam, ab238338), anti-SHH (Abcam, ab53281), and anti-SMO (Abcam, ab236465). GLI1 and GLI2 were evaluated for cytoplasmic and nuclear stain, while PTCH1, PTCH2, SHH, and SMO were evaluated for cytoplasmic stain. IHC was scored from 0 to 3 according to the stain intensity because a majority of cases showed a diffuse staining pattern.

Kim H.S., Kim Y.S., Lee C., Shin M.S., Kim J.W, & Jang B.G. (2019). Expression profile of sonic hedgehog signaling-related molecules in basal cell carcinoma. PLoS ONE, 14(11), e0225511.

+ Open protocol

+ Expand

Immunohistochemical Analysis of EPHB2, CD44, and β-catenin

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunohistochemistry was performed on 4-μm TMA sections using a Ventana BenchMark XT Staining systems (Leica Microsystems, Wetzlar, Germany) according to the manufacturer’s instructions. The primary antibodies used were anti-EPHB2 (1:700, R&D Systems, Minneapolis, MN, USA), anti-CD44 (1:100, Novocastra Laboratories Ltd., Newcastle upon Tyne, UK), and anti-β-catenin (1:800, 17C2, Novocastra Laboratories). The expression of EPHB2 and CD44 was determined by examining the tumor cell membrane. For each tumor, the intensity and percentage of tumor cells expressing EPHB2 (n = 567) or CD44 (n = 87) were evaluated. Histoscores (H-scores) were calculated by multiplying the intensity score (0, negative; 1, weak; 2, moderate; and 3, strong) and percentage of positive tumor cells (range, 0 to 100), ranging from 0 to 300. For statistical analyses for EPHB2, we used a cutoff of 40 on the basis of the distribution of the H-scores (median value, 40). CRCs with H-score of 40 or lower were classified as negative, while cases with H-score higher than 40 were classified as positive. β-Catenin staining was considered positive when more than 10% of tumor cell nuclei were strongly stained.

Jang B.G., Kim H.S., Chang W.Y., Bae J.M, & Kang G.H. (2018). Prognostic Significance of EPHB2 Expression in Colorectal Cancer Progression. Journal of Pathology and Translational Medicine, 52(5), 298-306.

+ Open protocol

+ Expand

Immunohistochemistry of SMOC2 and BRAF

Check if the same lab product or an alternative is used in the 5 most similar protocols

According to the manufacturer’s instructions, immunohistochemistry was performed on 4-μm TMA sections using a Ventana BenchMark XT Staining systems (Leica Microsystems, Wetzlar, Germany). The primary antibodies used were anti-SMOC2 (OriGene, Rockville, MD; 1:30) and anti-BRAF (V600E) (Spring Bioscience, VE1; 1:50). Cytoplasmic SMOC2 staining was scored from 0 to 3 according to the stain intensity and each case was considered as positive when score is more than 1.

Kim H.S., Choi J.H., Lee J.Y., Kang J., Myung J.K., Kim W.H, & Jang B.G. (2020). Downregulation of SMOC2 expression in papillary thyroid carcinoma and its prognostic significance. Scientific Reports, 10, 4853.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!